

STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2021

(Rs.in Lakh, except per share data)

PART I		PARTICULARS	STANDALONE				CONSOLIDATED			
			QUARTER ENDED		YEAR ENDED		QUARTER ENDED		YEAR ENDED	
			30.06.2021	31.03.2021	30.06.2020	31.03.2021	30.06.2021	31.03.2021	30.06.2020	31.03.2021
			(Unaudited)	(Audited) (Refer Note 2)	(Unaudited)	(Audited)	(Unaudited)	(Audited) (Refer Note 2)	(Unaudited)	(Audited)
1	Revenue from operations	14,572.85	16,845.92	12,116.94	60,004.83	33,082.64	32,662.41	30,574.39	118,710.31	
2	Other income	383.20	173.67	99.09	546.83	1,054.96	209.30	46.62	498.42	
3	Total income	14,956.05	17,019.59	12,216.03	60,551.66	34,137.60	32,871.71	30,621.01	119,208.73	
4	Expenses									
	Cost of materials consumed	7,965.38	9,001.42	8,221.07	38,417.99	19,328.26	14,834.38	9,954.17	48,803.22	
	Purchase of stock in trade	277.23	1,250.64	30.80	1,604.49	1,325.98	1,061.33	3,547.96	7,813.59	
	Changes in inventories of finished goods/WIP/stock in trade	246.03	291.53	(576.98)	(2,182.59)	(2,354.75)	699.66	2,827.32	1,732.00	
	Employee benefits expense	1,130.09	1,151.51	706.35	3,869.86	3,275.77	3,511.01	2,538.95	12,038.31	
	Finance costs	960.64	992.07	860.70	3,253.65	1,013.24	1,209.80	1,055.27	3,752.77	
	Depreciation and amortisation expense	644.09	656.29	305.76	1,928.30	1,341.14	1,182.61	948.06	4,429.42	
	Other expenses	3,036.04	3,086.31	2,107.76	12,107.82	6,950.83	7,512.50	6,598.01	30,129.85	
	Total Expenses	14,259.50	16,429.77	11,655.46	58,999.52	30,880.47	30,011.29	27,469.74	108,699.16	
5	Profit before exceptional items and share of profit / (loss) of associate (3-4)	696.55	589.82	560.57	1,552.14	3,257.13	2,860.42	3,151.27	10,509.57	
6	Exceptional items	-	-	50.32	50.32	-	-	-	-	
7	Profit before share of profit / (loss) of associate (5-6)	696.55	589.82	510.25	1,501.82	3,257.13	2,860.42	3,151.27	10,509.57	
8	Share of profit / (loss) of associate	-	-	-	-	(2.40)	0.06	-	0.06	
9	Profit before tax (7-8)	696.55	589.82	510.25	1,501.82	3,254.73	2,860.48	3,151.27	10,509.63	
10	Tax Expenses									
	- Current tax	125.35	109.89	91.94	277.92	830.43	882.30	845.58	2,735.69	
	- Deferred tax	97.98	266.41	37.43	395.78	46.64	406.45	249.70	1,238.14	
		223.33	376.30	129.37	673.70	877.07	1,288.75	1,095.28	3,973.83	
11	Profit for the period (9-10)	473.22	213.52	380.88	828.12	2,377.66	1,571.73	2,055.99	6,535.80	
12	Other comprehensive income									
A	(i) Items that will not be reclassified to profit or loss									
	Remeasurements of defined benefit plans	9.03	(32.88)	6.15	(49.46)	9.03	(38.78)	6.15	(55.36)	
	Changes in revaluation surplus	-	-	-	-	-	10,021.92	-	10,021.92	
	(ii) Income tax relating to Items that will not be reclassified to profit or loss	(3.16)	5.70	(2.15)	11.49	(3.16)	7.71	(2.15)	13.50	
B	(i) Items that will be reclassified to profit or loss									
	Exchange differences on translating the financial statements of foreign operations	-	-	-	-	334.65	(688.41)	459.55	1,369.98	
	(ii) Income tax relating to Items that will be reclassified to profit or loss	-	-	-	-	-	-	-	-	
	Other comprehensive income	5.87	(27.18)	4.00	(37.97)	340.52	9,302.44	463.55	11,350.04	
13	Total comprehensive income for the period (11+12)	479.09	186.34	384.88	790.15	2,718.18	10,874.17	2,519.54	17,885.84	
14	Profit / (loss) attributable to:									
	(i) Owners of the Company					2,235.70	1,426.53	1,538.81	5,096.34	
	(ii) Non-controlling interests					141.96	145.20	517.18	1,439.46	
15	Other comprehensive income attributable to:									
	(i) Owners of the Company					130.18	9,454.40	352.67	10,936.97	
	(ii) Non-controlling interests					210.34	(151.96)	110.88	413.07	
16	Total comprehensive income attributable to:									
	(i) Owners of the Company					2,365.88	10,880.93	1,891.48	16,033.31	
	(ii) Non-controlling interests					352.30	(6.76)	628.06	1,852.53	
17	Paid-up Equity Share Capital (Face Value Re.1/- per share)	1,275.91	1,274.98	1,212.54	1,274.98	1,275.91	1,274.98	1,212.54	1,274.98	
18	Other Equity				45,188.57				63,065.10	
19	Earnings per Share (EPS) (of Re.1/- each) (not annualised)									
	Basic (Rs.)	0.37	0.17	0.31	0.67	1.75	1.16	1.27	4.13	
	Diluted (Rs.)	0.31	0.15	0.31	0.60	1.48	1.03	1.27	3.68	



Signature

CFS
Camlin
Fine Sciences

Registered Office:

Camlin Fine Sciences Ltd. F/11-12, WICEL, Opp. SEEPZ, Central Road, Andheri East, Mumbai 400 093, India.
CIN: L74100MH1993PLC075361 | ISO 22000 Certified Company



+91 22 6700 1000



+91 22 2832 4404



corporate@camlinfs.com



www.camlinfs.com

Notes to financial results:

- The above results which are published in accordance with Regulation 33 of the SEBI (Listing Obligation & Disclosure Requirements), 2015, as amended, have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on August 13, 2021. The financial results are in accordance with the Indian Accounting Standards (Ind AS) as prescribed under Section 133 of the Companies Act, 2013 read with Rule 3 of the Companies (Indian Accounting Standards) Rules, 2015, as amended from time to time.
- The figures for the quarter ended March 31, 2021 as reported in these results are the balancing figures between audited figures in respect of the year ended March 31, 2021 and the published year to date figures up to the end of the third quarter of the relevant financial year. Also, the figures upto the end of the third quarter had only been reviewed and not subjected to audit.
- Other income / Other expense above includes net foreign exchange gain / (loss) for each reporting period as under:

Rs. In Lakh.

Particulars	STANDALONE				CONSOLIDATED			
	QUARTER ENDED			YEAR ENDED	QUARTER ENDED			YEAR ENDED
	30.06.2021	31.03.2021	30.06.2020	31.03.2021	30.06.2021	31.03.2021	30.06.2020	31.03.2021
	(Unaudited)	(Audited) (Refer Note 2)	(Unaudited)	(Audited)	(Unaudited)	(Audited) (Refer Note 2)	(Unaudited)	(Audited)
Other Income	268.37	104.57	0.63	-	986.41	-	-	-
Other Expense	-	-	-	872.68	-	88.63	321.87	1,488.52
Total Exchange gain / (loss)	268.37	104.57	0.63	(872.68)	986.41	(88.63)	(321.87)	(1,488.52)

- Finance costs include foreign exchange gain / (loss) for each reporting period as under:

Rs. In Lakh.

Particulars	STANDALONE				CONSOLIDATED			
	QUARTER ENDED			YEAR ENDED	QUARTER ENDED			YEAR ENDED
	30.06.2021	31.03.2021	30.06.2020	31.03.2021	30.06.2021	31.03.2021	30.06.2020	31.03.2021
	(Unaudited)	(Audited) (Refer Note 2)	(Unaudited)	(Audited)	(Unaudited)	(Audited) (Refer Note 2)	(Unaudited)	(Audited)
Exchange gain	-	-	-	224.79	-	-	20.28	588.66
Exchange loss	98.30	25.20	20.57	-	42.26	76.74	-	-
Total Exchange gain / (loss)	(98.30)	(25.20)	(20.57)	224.79	(42.26)	(76.74)	20.28	588.66

- During the quarter ended June 30, 2021, the Company has issued and allotted 92,900 equity shares of Re.1 each respectively at a premium of Rs. 49 per equity share aggregating to INR 46.45 lakh under Employees Stock Option Scheme, 2018 (ESOP-2018). No employee stock options under ESOP -2018 or ESOP -2020 have lapsed during the quarter ended June 30, 2021.
- Supreme People's Court of China vide its judgement dated February 19, 2021 had imposed a penalty of RMB 159.32 million (about USD 25 million / INR 18,000 lakh) including right protection cost of RMB 3.49 million (about USD 0.55 million / INR 390 lakh) on our JV partner Wanglong Technology (being 49% stake holder in Company's subsidiary CFS Wanglong Flavors (Ningbo) Co., Ltd. (CFSWL) & others for alleged infringement of intellectual property used in the process for manufacturing Vanillin. Further, 7% of the aforesaid penalty amounting to RMB 11.15 million (about USD 1.70 million / INR 1,265 lakh) had also been levied to the subsidiary Company. Consequent to the Order, as an abundant legal caution, the production of Vanillin at the subsidiary's manufacturing facility in China has been stopped till further directions of the Court.
In the opinion of the management, based on the discussions with the JV Partner, the findings and allegations of the Honourable Court are not based on the facts and that the order passed by the Court is arbitrary. As a co-defendant with the JV Partner, the subsidiary company has preferred an application for retrial of the aforesaid order before Supreme People's Court of China which is likely to be heard in last week of August 2021. Process has also been initiated to move the Court to stay the processing of above order until the retrial application is heard. The management is confident of a favourable decision in the retrial proceedings and that no penalty will be sustained and that consequently the production is expected to restart in a very near future.
Further in terms of the shareholders' agreement dated April 28, 2017 and its subsequent amendments, Company and its subsidiary, CFSWL are indemnified against penalty and or legal consequences emanating from the violation of IP rights.
Under these circumstances, no impairment of the investment value of CFSWL and or other receivables is envisaged at this juncture in standalone financial results. Similarly, no impairment of goodwill and /or property, plant and equipment is envisaged in the consolidated financial results.
- Company / Group has considered the possible effects that may result from the pandemic relating to COVID-19 in the preparation of the financial results including the recoverability of carrying amounts of financial and non-financial assets. In developing the assumptions relating to the possible future uncertainties in the global economic conditions because of this pandemic, the Company / Group, has used internal and external sources of information on the expected future performance of the Company and the Group, its ability to meet its liabilities and in assessing the recoverability and carrying values of its assets. There is no material change in the internal control environment in the group. The impact of COVID-19 on the Group's financial results may differ from that estimated as at the date of approval of these consolidated financial results.
- The Company's operations constitute a single business segment in Fine Chemicals.
- Figures for previous periods have been regrouped/rearranged wherever necessary.

Place: Loravala
Date: August 13, 2021



FOR CAMLIN FINE SCIENCES LIMITED

Ashish S. Dandekar
Ashish S. Dandekar
Chairman & Managing Director

CFS[®]
Camlin
Fine Sciences



Registered Office:

Camlin Fine Sciences Ltd. F/11-12, WICEL, Opp. SEEPZ, Central Road, Andheri East, Mumbai 400 093, India.

CIN: L74100MH1993PLC075361 | ISO 22000 Certified Company

+91 22 6700 1000



+91 22 2832 4404



corporate@camlinfs.com



www.camlinfs.com

KALYANIWALLA & MISTRY LLP

CHARTERED ACCOUNTANTS

To,
The Board of Directors
Camlin Fine Sciences Limited,
WICEL, F-11/12, Opp. SEEPZ Main Gate,
Central Road, SEEPZ,
Andheri- (East).

LIMITED REVIEW REPORT

1. We have reviewed the accompanying Statement of Unaudited Standalone Financial Results of Camlin Fine Sciences Limited (“the Company”), for the quarter ended June 30, 2021. This statement which has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 ‘Interim Financial Reporting’ (“Ind AS 34”), prescribed under Section 133 of the Companies Act, 2013, read with relevant rules issued thereunder, as applicable and other accounting principles generally accepted in India is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.
2. We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410, “Review of Interim Financial Information Performed by the Independent Auditor of the Entity”, issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial results are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
3. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement of Unaudited Standalone Financial Results prepared in accordance with the applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.
4. Attention is drawn to the fact that the figures for the 3 months ended March 31, 2021 as reported in these financial results are the balancing figures between audited figures in respect of the full previous financial year and the published year to date figures up to the third quarter of the previous financial year. The figures up to the end of the third quarter of previous financial year had only been reviewed and not subjected to audit.
5. We draw attention to Note 6 to the Financial Results relating to the decision of the Supreme People’s Court of China which has imposed penalty amounting to RMB 159.32 million on the JV partner in the subsidiary company and others for alleged infringement of intellectual property used in the manufacturing process. An amount of RMB 11.15 million i.e. INR 1265 lakh which is 7% of the total penalty imposed is attributed to the subsidiary i.e. CFS Wanglong Flavours (Ningbo) Co. Ltd. As an abundant legal caution, the Company has stopped the production facility till further directions of the court. As per the terms of the shareholders’ agreement dated April 28, 2017 and amendments made thereafter, the subsidiary company and its subsidiary company are indemnified against penalty and or legal consequences emanating from the violation of the IP rights. As a co-defendant with the JV Partner, the subsidiary company has preferred



LLP IN : AAH - 3437


REGISTERED OFFICE : ESPLANADE HOUSE, 29, HAZARIMAL SOMANI MARG, FORT, MUMBAI 400 001
TEL.: (91) (22) 6158 6200, 6158 7200 FAX : (91) (22) 6158 6275

**KALYANIWALLA
& MISTRY LLP**

an application for retrial of the aforesaid order before Supreme People's Court of China. In the opinion of the Management, based on the above and for reasons as more fully discussed in the aforesaid note, no impairment of the investment value or in respect of other receivables from the subsidiary company is required.

Our opinion is not modified in respect of these matters.

**For KALYANIWALLA & MISTRY LLP
CHARTERED ACCOUNTANTS
Firm Registration Number 104607W/W100166**



**FARHAD M. BHESANIA
PARTNER
Membership Number 127355
UDIN: 21127355AAAAGY1716**

Place: Mumbai
Date: August 13, 2021

KALYANIWALLA & MISTRY LLP

CHARTERED ACCOUNTANTS

To,
The Board of Directors
Camlin Fine Sciences Limited
WICEL, F-11/12, Opp. SEEPZ Main Gate,
Central Road, SEEPZ,
Andheri- (East), Mumbai-400096

LIMITED REVIEW REPORT

1. We have reviewed the accompanying Statement of Unaudited Consolidated Financial Results of Camlin Fine Sciences Limited (the "Parent"), and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group") and associates for the quarter ended June 30, 2021 ("the Statement"), being submitted by the Parent pursuant to the requirement of Regulation 33 of the Securities and Exchange Board of India ("the SEBI") (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 'Interim Financial Reporting' ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, read with relevant rules issued thereunder, as applicable and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial results are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

4. Attention is drawn to the fact that the figures for the 3 months ended March 31, 2021 as reported in these financial results are the balancing figures between audited figures in respect of the full previous financial year and the published year to date figures up to the third quarter of the previous financial year. The figures up to the end of the third quarter of previous financial year had only been reviewed and not subjected to audit.
5. We draw attention to Note 6 to the Financial Results relating to the decision of the Supreme People's Court of China which has imposed penalty amounting to RMB 159.32 million on the JV partner in the subsidiary company and others for alleged infringement of intellectual property used in the manufacturing process. An amount of RMB 11.15 million i.e. INR 1,265 lakh which is 7% of the total penalty imposed is attributed to the subsidiary i.e. CFS Wanglong Flavours (Ningbo) Co. Ltd. As an abundant legal caution, the Company has stopped the production facility till further directions of the
As per the terms of the shareholders' agreement dated April 28, 2017 and amendments made



LLP IN : AAH - 3437

REGISTERED OFFICE : ESPLANADE HOUSE, 29, HAZARIMAL SOMANI MARG, FORT, MUMBAI 400 001
TEL.: (91) (22) 6158 6200, 6158 7200 FAX : (91) (22) 6158 6275

thereafter, the subsidiary company and its subsidiary company are indemnified against penalty and or legal consequences emanating from the violation of the IP rights. As a co-defendant with the JV Partner, the subsidiary company has preferred an application for retrial of the aforesaid order before Supreme People's Court of China. In the opinion of the management, based on the above and for reasons as more fully discussed in the aforesaid note, no impairment of cash generating unit consisting of property, plant and equipment of the said subsidiary or on goodwill on consolidation in respect of the said subsidiary company is required.

Our opinion is not modified in respect of this matter.

6. The Statement includes the results of the following entities:
 - i. CFS Europe S.p.A.
 - ii. CFS Do Brasil Importacao E Exportacao De Aditivos Alimenticios LTDA
 - iii. Solentus North America Inc
 - iv. CFS North America LLC
 - v. Dresen Quimica, S.A.P.I. de C.V.
 - vi. Inovel, S.A.S.
 - vii. Industrias Petrotec De Mexico S.A De C.V.
 - viii. Nuvel, S.A.C.
 - ix. Britec, S.A.
 - x. Grinel, S.R.L.
 - xi. Chemolutions Chemicals Ltd.
 - xii. CFS Wanglong Flavours (Ningbo) Co. Ltd.
 - xiii. CFS Argentina S.A.
 - xiv. CFS Chile S.p.A
 - xv. CFS Pahang Asia Pte Ltd.
 - xvi. Fine Lifestyle Brands Ltd.
 - xvii. AlgalR NutraPharma Private Limited
7. Based on our review and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Ind AS and other accounting practices generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.
8. We did not review the interim financial results of eleven subsidiaries incorporated outside India and a subsidiary in India included in the consolidated unaudited financial results, whose interim financial results reflect total revenues of Rs. 21,856.94 lakh, total net profit after tax of Rs. 1,706.44 lakh and total comprehensive income of Rs. 414.99 lakh. The Consolidated financial results for the quarter ended June 30, 2021, also includes share of net profit of Nil in respect of an associate whose interim financial results were not reviewed by us. These interim financial results have been reviewed by other auditors whose reports have been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries and an associate, is based solely on the reports of the other auditors and the procedures performed by us as stated in paragraph 3 above.

In respect of eleven subsidiaries located outside India whose interim financial results and other financial information have been prepared in accordance with accounting principles generally accepted in their respective countries and which have been reviewed by other auditors under generally accepted



**KALYANIWALLA
& MISTRY LLP**


auditing standards applicable in their respective countries. The Company's management has converted the interim financial results of such subsidiaries located outside India from accounting principles generally accepted in their respective countries to accounting principles generally accepted in India (Indian Accounting Standards "Ind AS"). We have reviewed these conversion adjustments made by the Company's management. Our conclusion in so far as it relates to the balances and affairs of such subsidiaries located outside India is based on the report of the other auditors and the conversion adjustments made by the management of the Company and reviewed by us.

Our conclusion on the statement is not modified in respect of the above matters.

9. The Statement includes interim financial results of three subsidiaries incorporated outside India included in the consolidated unaudited financial results, whose interim financial results reflect total revenue of Rs. 512.47 lakh, total net profit after tax of Rs. 36.35 lakh, total comprehensive income of Rs. (22.94) lakh. The Statement of financial results for the quarter ended June 30, 2021, also includes share of net loss of Rs. 2.40 lakh in respect of an associate. These interim financial results of three subsidiaries and an associate are not reviewed as of the date of this report and have been included in the interim financial results on the basis of the Unaudited Management Accounts. According to the information and explanations given to us by the management, these interim financial results are not material to the Group.

Our report on the Statement is not modified in respect of our reliance on the Unaudited Management Accounts and other financial information furnished by the management.

**For KALYANIWALLA & MISTRY LLP
CHARTERED ACCOUNTANTS
Firm Registration Number 104607W/W100166**



**FARHAD M. BHESANIA
PARTNER
Membership Number 127355
UDIN: 21127355AAAAGZ5901**

Place: Mumbai
Dated: August 13, 2021

(Rs.in Lakh)

STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2021									
No.	PARTICULARS	STANDALONE				CONSOLIDATED			
		QUARTER ENDED		YEAR ENDED		QUARTER ENDED		YEAR ENDED	
		30.06.2021	31.03.2021	30.06.2020	31.03.2021	30.06.2021	31.03.2021	30.06.2020	31.03.2021
		(Unaudited)	(Audited)	(Unaudited)	(Audited)	(Unaudited)	(Audited)	(Unaudited)	(Audited)
1	Total Income from Operations	14,572.85	16,845.92	12,116.94	60,004.83	33,082.64	32,662.41	30,574.39	118,710.31
2	Net Profit from ordinary activities after tax	473.22	213.52	380.88	828.12	2,377.66	1,571.73	2,055.99	6,535.80
3	Net Profit for the period after tax and non-controlling interests (after extraordinary items)	-	-	-	-	2,235.70	1,426.53	1,538.81	5,096.34
4	Total Comprehensive Income for the period	479.09	186.34	384.88	790.15	2,718.18	10,874.17	2,519.54	17,885.84
5	Equity Share Capital	1,275.91	1,274.98	1,212.54	1,274.98	1,275.91	1,274.98	1,212.54	1,274.98
6	Other Equity				45,188.57				63,065.10
7	Earnings per share (before and after extraordinary items) (of Re 1/-each)								
	-Basic Rs.	0.37	0.17	0.31	0.67	1.75	1.16	1.27	4.13
	-Diluted Rs.	0.31	0.15	0.31	0.60	1.48	1.03	1.27	3.68

1 The above information is an extract of the detailed format of unaudited results for the quarter ended June 30, 2021 filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the unaudited results for the quarter ended June 30, 2021 are available on the Company's website, www.camlinfs.com and the Stock Exchange websites i.e. www.bseindia.com and www.nseindia.com.

Place: Lonavala
Date: August 13, 2021



FOR CAMLIN FINE SCIENCES LIMITED

Ashish S. Dandekar

Ashish S. Dandekar
Chairman & Managing Director

CFS
Camlin
Fine Sciences

Registered Office:

Camlin Fine Sciences Ltd. F/11-12, WICEL, Opp. SEEPZ, Central Road, Andheri East, Mumbai 400 093, India.
CIN: L74100MH1993PLC075361 | ISO 22000 Certified Company

+91 22 6700 1000



+91 22 2832 4404



corporate@camlinfs.com



www.camlinfs.com